The first mRNA flu shot is now available. Here’s who can get it.
Moderna's mRNA flu vaccine, mFlusiva, is now available in the U.S. for people 50 and older. It was approved after a trial showed 27% higher effectiveness than standard flu shots. The FDA approved it for adults 50-64 and accelerated approval for those 65+. Insurance coverage varies, with Medicare covering it and private insurers expected to, but Medicaid coverage is uncertain. The vaccine is priced at around $171 per dose without insurance. Pharmacies like CVS and Walgreens are beginning to stock
How this was made
The 30-second read
Why it matters
Regulatory clearance creates a new revenue stream and may influence competitor strategies in the flu vaccine space.
Market read
The approval introduces a novel flu vaccine, potentially reshaping the seasonal flu market and offering investors a new growth catalyst.
What to watch
Pricing and reimbursement challenges may limit revenue growth.
Background
Moderna's mFlusiva is the first FDA‑approved mRNA flu vaccine, targeting adults 50 and older.
Ticker impact
FDA approved Moderna's mFlusiva mRNA flu vaccine for adults 50+.
Potential upside as investors price in new product revenue.
First-time approval of a novel mRNA flu shot, a material product launch for a large biotech.
Market effects
May accelerate mRNA platform adoption across vaccine market.
U.S. flu vaccine market sees new competitor; potential spillover to global markets.
Sets precedent for mRNA flu vaccines worldwide.
Counterpoint
Adoption could be slow due to limited supply and insurance coverage uncertainty.
Key entities
- CompanyModerna
Biotech firm developing mRNA vaccines.
